{"entity":{"id":"nct04188548","kind":"trial","name":"EMBER imlunestrant early study","aka":["A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer"],"tldr":"This early study tests imlunestrant, originally called LY3484356, alone or with other cancer therapies. It studies safety and activity in advanced breast or endometrial cancer.","summary":"This early study tests imlunestrant, originally called LY3484356, alone or with other cancer therapies. It studies safety and activity in advanced breast or endometrial cancer.\n\nInterventional study registered as NCT04188548, sponsored by Eli Lilly and Company. Registry phase: 1. Registry enrollment is 379 participants (actual). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT04188548","url":"https://clinicaltrials.gov/study/NCT04188548"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT04188548"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["abemaciclib","alpelisib","everolimus","imlunestrant","pertuzumab","trastuzumab"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04188548","phase":"1","setting":"Advanced or metastatic breast cancer or endometrial cancer","sponsor":"Eli Lilly and Company","participation":[{"nct":"NCT04188548","source":"https://clinicaltrials.gov/study/NCT04188548","fetchedAt":"2026-10-10T20:54:21.768016Z","studySha256":"8fb0a233cc774946ca0cafe7aa1355395450b9c50d45ba9d60499809cb690dee","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-22","leadSponsor":"Eli Lilly and Company","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":379,"enrolmentType":"ACTUAL","siteCount":74,"recruitingSiteCount":0,"countries":["Australia","Belgium","France","Japan","South Korea","Spain","Taiwan","United States"]}],"started":"2019-12-10","startedType":"actual","enrolled":379,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04188548/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/"},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"},{"id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}